13S130: Plenary II

Abstract Moderator(s)

• 

  Gregg Silverman

  Professor, Department of Medicine
  NYU School of Medicine
  New York, NY, United States

  Disclosure(s): Bristol-Myers Squibb(BMS): Consultant (Ongoing)
• 

  Tracy Frech, MD, MS

  Vanderbilt University Medical Center
  Nashville, TN, United States

  Disclosure(s): No financial relationships to disclose

Plenary abstract session.

Presentations:

• 11:30 AM – 11:40 AM Eastern Time

  Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry
  

  Presenting Author: Hafsah Nabi, MD – DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark
• 11:40 AM – 11:45 AM Eastern Time

  Q&A
  
• 11:45 AM – 11:55 AM Eastern Time

  Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
  

  Presenting Author: Thomas Dörner, MD – Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin
• 11:55 AM – 12:00 PM Eastern Time

  Q&A
  
• 12:00 PM – 12:10 PM Eastern Time

  Computational Drug Repositioning and 3D Skin Models Identify EGFR and PI3K Inhibitors as Anti-fibrotic Targets for Systemic Sclerosis
  

  Presenting Author: Dillon Popovich, BS – Dartmouth College
• 12:10 PM – 12:15 PM Eastern Time

  Q&A
  
• 12:15 PM – 12:25 PM Eastern Time

  Medication Co-pay Modifies Treatment Adherence in Patients with Systemic Lupus Erythematosus
  

  Presenting Author: Raisa Lomanto Silva, MD – University of Pittsburgh Medical Center
• 12:25 PM – 12:30 PM Eastern Time

  Q&A
  
• 12:30 PM – 12:40 PM Eastern Time

  Peripheral Blood DNA Methylation-based Machine Learning Models for Prediction of Knee Osteoarthritis Progression: Biospecimens and Data from the Osteoarthritis Initiative and Johnston County Osteoarthritis Project
  

  Presenting Author: Matlock A. Jeffries, MD, FACP, FACR – Oklahoma Medical Research Foundation
• 12:40 PM – 12:45 PM Eastern Time

  Q&A
  
• 12:45 PM – 12:55 PM Eastern Time

  Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
  

  Presenting Author: Marilyn Pike, MD, PhD – MedPharm consulting, Inc.
• 12:55 PM – 1:00 PM Eastern Time

  Q&A